The Clorox Company $CLX Shares Acquired by Focus Partners Wealth

Focus Partners Wealth increased its holdings in shares of The Clorox Company (NYSE:CLX - Free Report) by 34.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,936 shares of the company's stock after purchasing an additional 3,824 shares during the period. Focus Partners Wealth's holdings in Clorox were worth $2,199,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Integrity Alliance LLC. purchased a new stake in Clorox during the 1st quarter worth $419,000. Ransom Advisory Ltd purchased a new stake in Clorox during the 1st quarter worth $35,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Clorox by 3.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,157,257 shares of the company's stock valued at $170,406,000 after buying an additional 41,485 shares during the last quarter. Woodline Partners LP boosted its position in Clorox by 253.7% in the 1st quarter. Woodline Partners LP now owns 10,407 shares of the company's stock valued at $1,532,000 after buying an additional 7,465 shares during the last quarter. Finally, Empowered Funds LLC boosted its position in Clorox by 109.9% in the 1st quarter. Empowered Funds LLC now owns 46,534 shares of the company's stock valued at $6,852,000 after buying an additional 24,360 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Wells Fargo & Company decreased their price objective on shares of Clorox from $138.00 to $130.00 and set an "equal weight" rating for the company in a research report on Friday, September 5th. Barclays decreased their price objective on shares of Clorox from $129.00 to $119.00 and set an "underweight" rating for the company in a research report on Tuesday, July 15th. Jefferies Financial Group decreased their price objective on shares of Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. UBS Group decreased their price objective on shares of Clorox from $150.00 to $134.00 and set a "neutral" rating for the company in a research report on Thursday, July 17th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Clorox from $133.00 to $135.00 and gave the company a "neutral" rating in a research report on Monday, September 8th. One analyst has rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Reduce" and an average target price of $142.18.

Insider Activity

In related news, COO Eric H. Reynolds sold 15,041 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer directly owned 54,221 shares in the company, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.57% of the stock is owned by company insiders.

Clorox Price Performance

Shares of NYSE:CLX opened at $124.79 on Wednesday. The firm's 50 day moving average is $124.22 and its two-hundred day moving average is $131.86. The Clorox Company has a 52 week low of $116.53 and a 52 week high of $171.37. The firm has a market capitalization of $15.26 billion, a P/E ratio of 19.14, a PEG ratio of 0.99 and a beta of 0.52. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.24 by $0.63. The company had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. Clorox's revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, November 6th. Stockholders of record on Wednesday, October 22nd will be issued a $1.24 dividend. The ex-dividend date is Wednesday, October 22nd. This represents a $4.96 annualized dividend and a dividend yield of 4.0%. Clorox's dividend payout ratio (DPR) is 76.07%.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.